1. 2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy. (September 2015) Authors: Van Cutsem, E.; Ciardiello, F.; Seitz, J.F.; Hofheinz, R.D.; Verma, U.; Garcia-Carbonero, R.; Grothey, A.; Miriyala, A.; Kalmus, J.; Shapiro, J.; Falcone, A.; Zaniboni, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2305 Randomized phase 2/3 trial of transcatheter arterial chemoembolization (TACE) plus sunitinib or placebo in patients with hepatocellular carcinoma (HCC) (PRODIGE 16/SATURNE study): Results of the Phase II part. (September 2015) Authors: Hebbar, M.; Heurgue-Berlot, A.; Boige, V.; Le Malicot, K.; Bernard-Chabert, B.; Marcus, C.; Dharancy, S.; Sergent, G.; Perarnau, J.M.; Ehrhard, F.; Ollivier-Hourmand, I.; Vergniol, J.; Michel, P.; Edeline, J.; Rinaldi, Y.; Seitz, J.F.; Lepage, C.; De Baere, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S434 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2352 Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma: Final results of the SUN-CK phase II trial from GERCOR IRC. (September 2015) Authors: Neuzillet, C.; Seitz, J.F.; Fartoux, L.; Malka, D.; Lledo, G.; Tijeras-Raballand, A.; De Gramont, A.; Ronot, M.; Bouattour, M.; Dreyer, C.; Granier, M.; Benner, S.; Amin, A.; Bourget, P.; Hadengue, A.; Roldan, N.; Chibaudel, B.; Raymond, E.; Faivre, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S452 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2355 Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first- line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM). (September 2015) Authors: Bachet, J.B.; Hammel, P.; Desrame, J.; Chibaudel, B.; Debourdeau, P.; Dauba, J.; Lecomte, T.; Seitz, J.F.; Tournigand, C.; Aparicio, T.; Guerin Meyer, V.; Taieb, J.; Volet, J.; Bonnetain, F.; Louvet, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S453 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 560PImpact of Immune response-associated gene polymorphisms on tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation in the ACCORD-12/PRODIGE-2 phase III trial. (18th September 2017) Authors: Valerie, B.; Mollevi, C.; Chaput, N.; Gourgou, S.; Azria, D.; Seitz, J.F.; Bigot, L.; Juzyna, B.; Miran, I.; Gérard, J-P.; Laurent-Puig, P. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗